Btrc Antibody

What is Btrc and what is its role in biological systems?

Btrc (beta-TrCP1/BTRC), fully named Beta-Transducin Repeat Containing E3 Ubiquitin Protein Ligase, is a critical component of the ubiquitin-proteasome system. This protein functions primarily in the targeted degradation of phosphorylated substrates, playing essential roles in cell cycle regulation, signal transduction, and immune response pathways. As an E3 ubiquitin ligase, Btrc recognizes specific phosphorylation signals on target proteins, facilitating their ubiquitination and subsequent degradation by the proteasome. In research contexts, Btrc is frequently studied for its involvement in cancer progression, particularly for its apparent protective function against glioma through suppression of cell migration, invasion, and proliferation mechanisms .

What are the typical molecular characteristics of Btrc antibodies used in research?

Btrc antibodies used in research are typically generated against specific epitopes within the human beta-TrCP1 protein. Commercial antibodies are often derived from immunogens corresponding to amino acids 52-354 of human BTRC (NP_378663) or smaller fragments like Met1-Leu120 . These antibodies may be monoclonal (e.g., clone #763524 or OTI2H2) produced in mouse hosts, and are available in various formats including unconjugated, azide-free, and BSA-free preparations for specific applications . The theoretical molecular weight of Btrc is approximately 68.7 kDa, though the observed molecular weight on Western blots may vary (appearing at ~62 kDa, ~84 kDa, or other weights) due to post-translational modifications, relative charges, and experimental conditions .

What experimental applications are most suitable for Btrc antibody detection?

Btrc antibodies have been validated for multiple experimental applications, with varying optimal conditions for each method:

Researchers should note that each application requires specific optimization steps for the cell types and experimental conditions being used .

What species reactivity has been confirmed for commercial Btrc antibodies?

Commercial Btrc antibodies have demonstrated reactivity with human, mouse, and rat species, though with varying affinities across different antibody clones . Experimental validation has been documented in human cell lines including K562 (chronic myelogenous leukemia), A172 (glioblastoma), HEK293T (embryonic kidney), as well as mouse cell lines such as C2C12 (myoblast) . When using mouse-derived antibodies on mouse samples, researchers should be aware that Mouse-On-Mouse blocking reagents may be necessary for immunohistochemistry and immunocytochemistry experiments to reduce background signal .

How can Btrc expression be accurately quantified in comparative studies?

Accurate quantification of Btrc expression requires careful experimental design and appropriate controls. For Western blot analysis, researchers should use 80 μg of protein lysate subjected to 10% SDS-PAGE, followed by transfer to PVDF membranes . Probing should be done with primary anti-Btrc antibodies at 1:500 dilution (overnight at 4°C) and appropriate secondary antibodies (1:4,000 at room temperature for 2 hours) . For quantification, densitometric analysis using software such as ImageJ can normalize Btrc expression to housekeeping proteins like β-actin . When comparing endogenous versus overexpressed Btrc, distinguish between the two forms using dual detection with anti-Flag and anti-Btrc antibodies, which allows simultaneous visualization of exogenous (Flag-tagged) and endogenous protein levels .

What mechanisms underlie Btrc's anti-tumorigenic effects in glioma models?

Btrc exhibits significant anti-tumorigenic effects in glioma models through multiple mechanisms affecting cellular motility and proliferation. In experimental studies using U251 and U87 glioma cell lines, Btrc overexpression demonstrated:

• Significant inhibition of cell migration: Wound healing assays revealed that while control cells showed clear healing 48 hours post-scratch, Btrc-overexpressing cells showed minimal migratory activity. Quantitatively, migratory cell numbers decreased to 48.26±3.64% and 58.70±2.31% of control values in U251 and U87 cells, respectively .

• Suppression of invasive capacity: Using Matrigel-precoated Transwell chambers, researchers observed that Btrc overexpression reduced the number of invasive cells to 50.08±3.51% and 42.15±2.43% of control values in U251 and U87 cells, respectively .

These findings indicate that Btrc functions as a tumor suppressor in glioma by directly inhibiting cellular processes essential for cancer progression .

How do post-translational modifications affect Btrc antibody detection?

Post-translational modifications (PTMs) significantly impact Btrc antibody detection and can lead to variability in experimental results. The observed molecular weight of Btrc may differ substantially from the theoretical 68.7 kDa due to these modifications . Phosphorylation, ubiquitination, and SUMOylation of Btrc can alter epitope accessibility and protein migration patterns on gels. Additionally, Btrc exists in multiple isoforms (e.g., isoform 2), which exhibit different molecular weights and potentially different antibody reactivity .

When selecting antibodies, researchers should consider which domains or regions they target, particularly when studying specific PTMs or isoforms. The antibody's immunogen sequence (e.g., amino acids 52-354 versus Met1-Leu120) will determine its ability to detect modified forms of the protein . For comprehensive studies of Btrc's PTM status, complementary approaches such as phospho-specific antibodies, mass spectrometry, or mobility shift assays may be necessary alongside standard detection methods.

What are the critical controls for validating Btrc antibody specificity?

To ensure experimental rigor when working with Btrc antibodies, the following validation controls are essential:

Research indicates that HEK293T cells transfected with Btrc-expressing plasmids serve as effective positive controls, showing distinct bands at the expected molecular weight when probed with anti-Btrc antibodies . For mouse-derived antibodies used in mouse samples, Mouse-On-Mouse blocking reagents are crucial to reduce background interference .

What are the optimal conditions for immunocytochemical detection of Btrc?

For optimal immunocytochemical detection of Btrc, researchers should adhere to the following protocol parameters:

• Fixation: Use immersion fixation for adherent cell lines such as A172 (human glioblastoma) or COS7 (transfected with Btrc) .

• Antibody concentration: Apply Btrc primary antibody at 10 μg/mL for approximately 3 hours at room temperature . For the OTI2H2 clone, a 1:100 dilution is recommended .

• Detection system: Utilize fluorophore-conjugated secondary antibodies such as NorthernLights™ 557-conjugated Anti-Mouse IgG for visualization. Counterstain nuclei with DAPI to facilitate subcellular localization analysis .

• Special considerations: When using mouse-derived antibodies on mouse cells, implement Mouse-On-Mouse blocking reagents (e.g., catalog numbers PK-2200-NB and MP-2400-NB) to minimize background signal .

• Image acquisition: Capture high-resolution images focusing on both nuclear and cytoplasmic compartments, as Btrc has been observed to localize predominantly to nuclei in certain cell types such as A172 .

This approach enables precise visualization of Btrc's subcellular distribution, which is essential for understanding its functional dynamics in different cellular contexts.

How should Western blot protocols be optimized for Btrc detection?

For optimal Western blot detection of Btrc, researchers should implement the following protocol refinements:

• Sample preparation: Use 80 μg of protein lysate extracted with appropriate lysis buffers containing protease and phosphatase inhibitors to preserve Btrc integrity .

• Gel electrophoresis: Utilize 10% SDS-PAGE gels under reducing conditions, which provide optimal separation for detecting Btrc at its various molecular weights (ranging from 62-84 kDa) .

• Membrane transfer: Transfer proteins to PVDF membranes, which have shown superior performance compared to nitrocellulose for Btrc detection .

• Blocking: Block membranes with 5% non-fat milk or BSA in TBST for at least 1 hour at room temperature.

• Primary antibody incubation: Apply anti-Btrc antibody at 1:500-1:1000 dilution and incubate at 4°C overnight for optimal epitope binding .

• Secondary antibody parameters: Use HRP-conjugated anti-mouse IgG secondary antibodies (1:4,000 dilution) with 2-hour room temperature incubation .

• Detection method: Visualize using enhanced chemiluminescence substrates such as Pierce ECL Plus, with exposure optimization to capture the correct band intensity without saturation .

• Washing steps: Implement thorough washing (3 times for 15 minutes each) with TBST buffer between antibody incubations to minimize background signal .

Following this optimized protocol increases detection sensitivity and specificity, facilitating accurate quantification of Btrc expression levels.

What strategies improve flow cytometric analysis using Btrc antibodies?

For effective flow cytometric analysis using Btrc antibodies, researchers should implement these technical strategies:

• Sample preparation: Thoroughly dissociate cells and fix with paraformaldehyde (2-4%) followed by permeabilization with 0.1% Triton X-100 to enable antibody access to intracellular Btrc.

• Antibody titration: Optimize antibody concentration through titration experiments; a starting dilution of 1:100 is recommended based on validated protocols .

• Compensation controls: Include single-stained controls when performing multiparameter analysis to correct for spectral overlap.

• Gating strategy: Implement a hierarchical gating approach beginning with forward/side scatter to identify viable cells, followed by exclusion of doublets and selection of cells expressing markers of interest.

• Positive controls: Include samples of HEK293T cells transfected with Btrc overexpression plasmids alongside empty vector controls to establish positive signal thresholds .

• Quantification parameters: Analyze both the percentage of Btrc-positive cells and the mean fluorescence intensity (MFI) to capture both population heterogeneity and expression level differences.

This approach enables accurate assessment of Btrc expression at the single-cell level, particularly valuable when studying heterogeneous cell populations or transfection efficiency.

How can researchers differentiate between endogenous and exogenous Btrc in experimental systems?

Distinguishing between endogenous and exogenously expressed Btrc is critical for overexpression studies. Implement these approaches for clear differentiation:

• Epitope tagging: Utilize constructs with N- or C-terminal tags (Flag, HA, Myc) that allow detection of exogenous Btrc using tag-specific antibodies. Flag tags have been successfully employed in published Btrc overexpression systems .

• Dual antibody detection: Perform Western blots with both anti-Btrc and anti-tag antibodies on the same samples to visualize both protein populations simultaneously. The exogenous tagged protein typically displays a slightly higher molecular weight due to the tag addition .

• Immunofluorescence co-localization: For subcellular localization studies, co-stain with antibodies against Btrc and the epitope tag, followed by secondary antibodies with distinct fluorophores.

• Control samples: Include lysates from cells transfected with empty vector controls alongside Btrc-transfected samples to establish baseline endogenous expression levels .

• Band pattern analysis: In Western blots of cells transfected with Btrc overexpression plasmids, researchers should expect to observe distinct bands when immunoblotted with anti-Flag (detecting only exogenous Btrc) or anti-Btrc antibodies (detecting both endogenous and exogenous forms) .

This methodological approach allows researchers to accurately quantify the relative contributions of endogenous versus exogenous Btrc to observed phenotypes.

How should researchers address inconsistent Btrc detection across different experimental platforms?

When facing inconsistent Btrc detection across different platforms, implement this systematic troubleshooting approach:

• Verify antibody compatibility with each application. While some antibodies like MAB7675 and NBP2-71402 are validated for multiple applications, their optimal conditions vary significantly between Western blot (1:1000), immunocytochemistry (1:100), and flow cytometry (1:100) .

• Address platform-specific technical variations:

  • For Western blot inconsistencies: Compare reducing versus non-reducing conditions, as Btrc detection has been specifically validated under reducing conditions using Immunoblot Buffer Group 1 .

  • For immunofluorescence discrepancies: Optimize fixation methods and implement Mouse-On-Mouse blocking when using mouse-derived antibodies on mouse samples .

  • For flow cytometry variations: Standardize permeabilization protocols and compare cell surface versus intracellular staining approaches.

• Consider cell type-specific variations: Btrc expression patterns differ between cell lines, with documented detection in K562, A172, HEK293T, and C2C12 cells . When changing cell systems, revalidate antibody performance.

• Implementation of alternative detection methods: When standard Western blotting yields inconsistent results, consider Simple Western™ technology, which has successfully detected Btrc at approximately 84 kDa in K562 lysates .

Cross-validation across multiple detection platforms provides the most reliable characterization of Btrc expression patterns.

What are the critical parameters for quantitative analysis of Btrc in cell migration and invasion studies?

For robust quantitative analysis of Btrc in cell migration and invasion studies, researchers should standardize these critical parameters:

• Experimental timing: Standardize observation periods; wound healing assays for migration should be assessed at 48 hours post-scratch, when control samples typically show significant healing while Btrc-overexpressing samples remain largely unhealed .

• Quantification metrics:

  • For migration: Calculate the percentage of migratory cell numbers relative to control groups rather than absolute cell counts, which facilitates comparison across experiments. In U251 and U87 cells, Btrc overexpression decreased migration to 48.26±3.64% and 58.70±2.31% of control values, respectively .

  • For invasion: Quantify invasive cells using Matrigel-precoated Transwell chambers and express results as percentage relative to controls. Btrc overexpression reduced invasion to 50.08±3.51% and 42.15±2.43% in U251 and U87 cells, respectively .

• Sample preparation standardization: For invasion assays, maintain consistent Matrigel concentration and pre-coating procedures across experiments.

• Statistical analysis: Apply appropriate statistical tests with multiple biological replicates (minimum n=3) to ensure reproducibility and significance of observed differences.

• Visual documentation: Supplement quantitative data with representative images of migration and invasion assays to provide visual evidence of Btrc's effects .

These standardized approaches enable accurate assessment of Btrc's functional impact on cancer cell behavior.

How can subcellular localization of Btrc be accurately determined and quantified?

Accurate determination and quantification of Btrc's subcellular localization requires:

• High-resolution imaging techniques: Utilize confocal microscopy for precise subcellular localization. Immunofluorescence studies have revealed that Btrc predominantly localizes to nuclei in certain cell types, including A172 human glioblastoma cells .

• Co-localization markers: Implement nuclear counterstaining with DAPI alongside Btrc immunofluorescence to confirm nuclear localization . Additional organelle-specific markers can help identify potential cytoplasmic distributions.

• Quantitative co-localization analysis:

  • Calculate Pearson's correlation coefficient between Btrc and compartment-specific markers

  • Determine the nuclear-to-cytoplasmic ratio of Btrc signal intensity

  • Measure the percentage of cells showing predominant nuclear versus cytoplasmic localization

• Z-stack imaging: Acquire images at multiple focal planes to create 3D reconstructions that distinguish between genuine nuclear localization and signal from Btrc positioned above or below the nucleus.

• Fractionation validation: Complement imaging data with biochemical subcellular fractionation followed by Western blotting to quantify the relative abundance of Btrc in nuclear versus cytoplasmic extracts.

This multi-modal approach generates comprehensive data on Btrc's dynamic localization patterns, which may vary with cell type, cell cycle stage, and experimental conditions.

What approaches can validate functional relationships between Btrc and its potential target proteins?

To validate functional relationships between Btrc and potential target proteins, researchers should implement these complementary approaches:

• Co-immunoprecipitation assays: Utilize Btrc antibodies for immunoprecipitation followed by Western blotting for suspected target proteins, or vice versa. This confirms physical interaction between Btrc and candidate substrates.

• Ubiquitination assays: Since Btrc functions as an E3 ubiquitin ligase, perform in vitro or in vivo ubiquitination assays to determine whether candidate proteins undergo Btrc-dependent ubiquitination. This typically involves:

  • Overexpression of HA-tagged ubiquitin alongside Btrc

  • Immunoprecipitation of the candidate substrate

  • Western blotting with anti-HA antibodies to detect ubiquitinated forms

• Protein stability analysis: Measure the half-life of candidate proteins in the presence of wild-type versus dominant-negative Btrc, or following Btrc knockdown/overexpression. Cycloheximide chase experiments can assess protein degradation rates.

• Phosphorylation dependence: Since Btrc typically recognizes phosphorylated substrates, analyze whether phosphatase treatment or phosphorylation-site mutations in candidate proteins disrupt Btrc binding.

• Functional rescue experiments: In Btrc-depleted cells showing phenotypic changes (such as enhanced migration in glioma cells), test whether these changes can be reversed by reintroducing wild-type Btrc but not binding-deficient mutants .

These approaches collectively establish both physical and functional relationships between Btrc and its target proteins, elucidating the molecular mechanisms underlying Btrc's observed cellular effects.

How is Btrc being investigated in therapeutic approaches to glioblastoma and other cancers?

Btrc's demonstrated role in suppressing glioma cell migration, invasion, and proliferation positions it as a promising therapeutic target . Recent research reveals that Btrc overexpression significantly reduces the migratory and invasive capacity of glioblastoma cell lines (U251 and U87), suggesting that therapies enhancing Btrc expression or activity might impede cancer progression . Future therapeutic approaches may include:

• Small molecule stabilizers of Btrc protein to enhance its tumor-suppressive functions

• Targeted delivery of Btrc expression constructs to glioma cells

• Development of mimetic peptides that replicate Btrc's substrate recognition domains

• Identification of upstream regulators of Btrc expression as alternative therapeutic targets